VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYNE VYNE Therapeutics Inc.

Market Closed 02-14 16:00:00 EST

2.47

-0.01

-0.60%

盘后2.47

+0.000.00%

19:53 EST

High2.65	Low2.45	Vol110.30K
Open2.48	D1 Closing2.49	Amplitude7.96%
Mkt Cap36.44M	Tradable Cap24.98M	Total Shares14.75M
T/O280.58K	T/O Rate1.09%	Tradable Shares10.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VYNE","market":"US","secType":"STK","nameCN":"VYNE Therapeutics Inc.","latestPrice":2.47,"timestamp":1739566800000,"preClose":2.485,"halted":0,"volume":110301,"hourTrading":{"tag":"盘后","latestPrice":2.47,"preClose":2.47,"latestTime":"19:53 EST","volume":151,"amount":381.35,"timestamp":1739580831665},"delay":0,"floatShares":10115342,"shares":14751433,"eps":-0.858797,"marketStatus":"Market Closed","change":-0.015,"latestTime":"02-14 16:00:00 EST","open":2.48,"high":2.6477,"low":2.45,"amount":280575.9075795,"amplitude":0.079557,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.858797,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":2.485,"preHourTrading":{"tag":"盘前","latestPrice":2.51,"preClose":2.485,"latestTime":"09:29 EST","volume":19,"amount":47.69,"timestamp":1739543390095},"postHourTrading":{"tag":"盘后","latestPrice":2.47,"preClose":2.47,"latestTime":"19:53 EST","volume":151,"amount":381.35,"timestamp":1739580831665},"volumeRatio":1.5487058695394758,"impliedVol":3.8705,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VYNE/tweets","defaultTab":"tweets","newsList":[{"id":"2507495243","title":"VYNE Therapeutics (VYNE) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2507495243","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507495243?lang=en_us&edition=fundamental","pubTime":"2025-01-31 20:46","pubTimestamp":1738327605,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Stacy Ku maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.00. The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-vyne-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-vyne-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","COWN","BK4585","BK4566","BK4127","BK4007","VYNE","BK4207"],"gpt_icon":0},{"id":"2505784177","title":"EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo…","url":"https://stock-news.laohu8.com/highlight/detail?id=2505784177","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505784177?lang=en_us&edition=fundamental","pubTime":"2025-01-22 19:23","pubTimestamp":1737544980,"startTime":"0","endTime":"0","summary":"Edesa Biotech, Inc.  is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being characterized by patches appearing on both sides of the body. It is caused when pigment-producing cells  die or stop producing melanin as a result of an autoimmune disease, genetics, or a triggering event .A 2022 publication reported that the estimated prevalence of vitiligo patients in the U.S. is between 1.9 million and 2.8 million . This corresponds to a vitiligo market is projected to reach approximately $1 billion by 2030 . In support of this, the following two transactions show the potential for vitiligo treatments in development:. The company is continuing IND-enabling work in 2025 and has already received approval from Health Canada to conduct a Phase 2 tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/edsa-ind-expected-2025-eb06-112300368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","USAW.SI","BK4585","SIF",".IXIC","NVIW.SI","BK4007","SOC","BK4139","NQmain","BK4213","QID","QLD","BK4550","BK4532","PSQ","ARDS","MNQmain","EDSA","BK4187","VYNE","BK4588","SQQQ","TQQQ","USJW.SI","INCY"],"gpt_icon":1},{"id":"2503021693","title":"BRIEF-Vyne Therapeutics Cash Runway Extends Into Second Half Of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2503021693","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503021693?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:52","pubTimestamp":1736776335,"startTime":"0","endTime":"0","summary":"BRIEF-Vyne Therapeutics Cash Runway Extends Into Second Half Of 2026Jan 13 (Reuters) - Vyne Therapeutics Inc VYNE.O:VYNE THERAPEUTICS INC - CASH RUNWAY EXTENDS INTO SECOND HALF OF 2026Further company coverage: VYNE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O913K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2503306452","title":"Vyne Therapeutics Inc - Cash Runway Extends Into Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2503306452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503306452?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:56","pubTimestamp":1736772976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O913K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2501790155","title":"VYNE Therapeutics (VYNE) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2501790155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501790155?lang=en_us&edition=fundamental","pubTime":"2025-01-08 14:15","pubTimestamp":1736316922,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), with a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-vyne-gets-a-buy-from-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vyne-therapeutics-vyne-gets-a-buy-from-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2501255244","title":"Buy Rating Justified for VYNE Therapeutics Due to Promising Repibresib Developments and Competitive Advantages","url":"https://stock-news.laohu8.com/highlight/detail?id=2501255244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501255244?lang=en_us&edition=fundamental","pubTime":"2025-01-06 23:15","pubTimestamp":1736176519,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-justified-for-vyne-therapeutics-due-to-promising-repibresib-developments-and-competitive-advantages?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-justified-for-vyne-therapeutics-due-to-promising-repibresib-developments-and-competitive-advantages?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2501255714","title":"Promising Advancements of VYNE Therapeutics’ VYN201 Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2501255714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501255714?lang=en_us&edition=fundamental","pubTime":"2025-01-06 23:05","pubTimestamp":1736175916,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.7...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-advancements-of-vyne-therapeutics-vyn201-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-advancements-of-vyne-therapeutics-vyn201-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2501236321","title":"BRIEF-Vyne Therapeutics Completes Enrollment In Phase 2B Trial Evaluating VYN201","url":"https://stock-news.laohu8.com/highlight/detail?id=2501236321","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501236321?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:42","pubTimestamp":1736167373,"startTime":"0","endTime":"0","summary":"BRIEF-Vyne Therapeutics Completes Enrollment In Phase 2B Trial Evaluating VYN201Jan 6  - Vyne Therapeutics Inc VYNE.O:VYNE THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2B TRIAL EVALUATING VYN201 FOR THE TREATMENT OF NONSEGMENTAL VITILIGOVYNE THERAPEUTICS INC - TOP-LINE DATA FROM VYN201 TRIAL EXPECTED IN MID-2025Source text: nGNX41cC3vFurther company coverage: VYNE.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA3CMJ7G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2501956235","title":"Vyne Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo","url":"https://stock-news.laohu8.com/highlight/detail?id=2501956235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501956235?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:30","pubTimestamp":1736166600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA3CMJ7G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2501235951","title":"Vyne Therapeutics Inc - Top-Line Data From Vyn201 Trial Expected in Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501235951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501235951?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:30","pubTimestamp":1736166600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA3CMJ7G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2501123518","title":"VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo","url":"https://stock-news.laohu8.com/highlight/detail?id=2501123518","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501123518?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:30","pubTimestamp":1736166600,"startTime":"0","endTime":"0","summary":"Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligo. Top-line data from the 24-week double-blind portion of the trial expected in mid-2025. “Repibresib” approved as the non-proprietary name for VYN201 by USAN. BRIDGEWATER, N.J., Jan. 06, 2025  -- VYNE Therapeutics Inc.  , a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced completion of enrollment in the Phase 2b trial evaluating VYN201 gel for the treatment of nonsegmental vitiligo. Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025.About VitiligoVitiligo is a chronic autoimmune depigmenting disorder of the skin, characterized by the loss of pigment producing cells known as melanocytes. Vitiligo is th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vyne-therapeutics-completes-enrollment-phase-123000292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2500498337","title":"BTIG Initiates a Buy Rating on VYNE Therapeutics (VYNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2500498337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500498337?lang=en_us&edition=fundamental","pubTime":"2025-01-01 18:25","pubTimestamp":1735727111,"startTime":"0","endTime":"0","summary":"BTIG analyst Julian Harrison initiated coverage with a Buy rating on VYNE Therapeutics (VYNE – Research Report) on December 30 and set a price targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-initiates-a-buy-rating-on-vyne-therapeutics-vyne?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-initiates-a-buy-rating-on-vyne-therapeutics-vyne?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2493089700","title":"Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493089700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493089700?lang=en_us&edition=fundamental","pubTime":"2024-12-24 21:30","pubTimestamp":1735047059,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on VYNE Therapeutics (VYNE – Research Report) and Lye...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vyne-therapeutics-vyne-and-lyell-immunopharma-lyel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vyne-therapeutics-vyne-and-lyell-immunopharma-lyel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LYEL","HCSG","BK4505","BK4539","BK4007","BK4139","BK4137","VYNE"],"gpt_icon":0},{"id":"2493799375","title":"Promising Developments in VYNE Therapeutics’ VYN202 Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2493799375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493799375?lang=en_us&edition=fundamental","pubTime":"2024-12-24 02:15","pubTimestamp":1734977714,"startTime":"0","endTime":"0","summary":"Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on VYNE Therapeutics (VYNE – Research Report). The associated price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-developments-in-vyne-therapeutics-vyn202-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-developments-in-vyne-therapeutics-vyn202-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2493692387","title":"Vyne Therapeutics Price Target Maintained With a $5.75/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2493692387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493692387?lang=en_us&edition=fundamental","pubTime":"2024-12-23 23:05","pubTimestamp":1734966300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2024 10:05 ET (15:05 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","VYNE"],"gpt_icon":0},{"id":"2493769627","title":"Positive Phase 1 Results of VYN202 Bolster VYNE Therapeutics’ Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2493769627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493769627?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:55","pubTimestamp":1734965712,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.7...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-phase-1-results-of-vyn202-bolster-vyne-therapeutics-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-phase-1-results-of-vyn202-bolster-vyne-therapeutics-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE"],"gpt_icon":0},{"id":"2493696057","title":"H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2493696057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493696057?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:51","pubTimestamp":1734965465,"startTime":"0","endTime":"0","summary":"H.C. Wainwright notes VYNE Therapeutics (VYNE) disclosed positive topline data from the MAD portion of its Phase 1a SAD/MAD trial assessing VYN202 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-vynes-vyn202-becomes-pick-of-the-crop-after-mad-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-vynes-vyn202-becomes-pick-of-the-crop-after-mad-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2493763961","title":"VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2493763961","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493763961?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:17","pubTimestamp":1734963432,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics  shares were edging higher Monday morning after the biopharmaceutical company reported \"positive\" phase 1a results for its novel BD2-selective BET inhibitor VYN202.The company said the results support the inhibitor's potential as a new oral treatment for various immune-mediated disorders.VYN202 showed a favorable safety and tolerability profile without any drug-related adverse events in the phase 1a trial as well as \"robust pharmacodynamic activity,\" VYNE said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","VYNE"],"gpt_icon":0},{"id":"2493548437","title":"VYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2493548437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493548437?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:35","pubTimestamp":1734957321,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics (VYNE) announced positive results from the multiple ascending dose, MAD, portion of its Phase 1a SAD/MAD trial of VYN202. The Pha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-announces-results-from-mad-portion-of-phase-1a-sad-mad-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyne-therapeutics-announces-results-from-mad-portion-of-phase-1a-sad-mad-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE","BK4007"],"gpt_icon":0},{"id":"2493751600","title":"Vyne Therapeutics Inc - Vyn202 Shows Favorable Safety and Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2493751600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493751600?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:30","pubTimestamp":1734957001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nTUA70C6HC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vynetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":-0.1051},{"period":"3month","weight":-0.0852},{"period":"6month","weight":0.328},{"period":"1year","weight":0.1435},{"period":"ytd","weight":-0.2627}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.045848},{"month":2,"riseRate":0.375,"avgChangeRate":0.006288},{"month":3,"riseRate":0.428571,"avgChangeRate":0.048397},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.184881},{"month":5,"riseRate":0.571429,"avgChangeRate":0.038029},{"month":6,"riseRate":0,"avgChangeRate":-0.163623},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.064684},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.080327},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.032924},{"month":10,"riseRate":0.428571,"avgChangeRate":0.003758},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.045576},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.10607}],"exchange":"NASDAQ","name":"VYNE Therapeutics Inc.","nameEN":"VYNE Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VYNE Therapeutics Inc.,VYNE,VYNE Therapeutics Inc.股票,VYNE Therapeutics Inc.股票老虎,VYNE Therapeutics Inc.股票老虎国际,VYNE Therapeutics Inc.行情,VYNE Therapeutics Inc.股票行情,VYNE Therapeutics Inc.股价,VYNE Therapeutics Inc.股市,VYNE Therapeutics Inc.股票价格,VYNE Therapeutics Inc.股票交易,VYNE Therapeutics Inc.股票购买,VYNE Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction